Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Verve Therapeutics (VERV) has shared an update.
Verve Therapeutics, Inc. has announced the appointment of Troy Lister, Ph.D., as the new Chief Scientific Officer, effective June 21, 2024, succeeding the outgoing Andrew Bellinger, M.D., Ph.D. Bellinger will receive a severance package including continued salary, health benefits, and a lump sum, alongside immediate vesting of certain stock options. Additionally, Bellinger has agreed to provide advisory services post-departure under a new agreement, which includes compensation for his advice and allows option exercise rights, ensuring his expertise remains accessible to Verve Therapeutics.
Learn more about VERV stock on TipRanks’ Stock Analysis page.